Immuron
IMRN | NASDAQ
$0.90
+$0.02 (+2.82%)
At close: Nov 16, 2026, 4:00 PM ET
$0.92
+$0.02 (+1.72%)
After-hours:
Nov 16, 2026, 7:00 PM ET
+2.82%
(1D)No price chart data available for 1D timeframe.
Rating
39.5
+7.0 ptsFundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #542/1021 (Top 53%)
Key Statistics
Market Data
Market Cap $7.32M
1D Range
0.82 0.91
52W Range
0.70 1.84
Valuation (TTM)
PE -2.60
PB 0.96
EV/EBITDA -0.33
Valuation (NTM)
Forward PE N/A
Forward PEG 0.16
Price Target $0.00
Cash Flow
FCF Yield -29.4%
SBC Adj. FCF Yield -29.4%
SBC Impact N/A
Margins
Gross Margin 64.5%
Operating Margin -61.5%
FCF Margin -41.7%
Growth (CAGR)
Revenue 3Y | 5Y 178.3% |
36.7%
Dil EPS 3Y | 5Y 0.5% |
1.2%
FCF 3Y | 5Y -6.3% |
-17.8%
Returns
ROA -29.5%
ROE -31.9%
ROIC -36.4%
Financial Health
Net Cash
A$9.02M ($6.24M)
Current Ratio 7.17
Interest Coverage -321.88
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and ...
Sector Healthcare
Industry Biotechnology
Employees 7
IPO Date Jun 9, 2017
Website www.immuron.com.au
Fiscal Year July - June
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove IMRN